Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors.
A need remains for the development of more effective therapies for the treatment of rheumatoid arthritis (both NSAIDs and DMARDs). The NSAIDs remain the cornerstone of symptomatic therapy, but concern remains about their safety, potential for the delay in commencing definitive therapy and theoretical pro-inflammatory effects. Each of the NSAIDs reviewed here do provide an advantage over therapies previously available and should prove to be useful additions to the rheumatologists' therapeutic armament.
Richardson
C E
CE
Department of Rheumatology and Rehabilitation, University of Leeds, UK.
Emery
P
P
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002074:Butanones / Q000009:adverse effects / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors*; D004064:Digestive System / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D000077239:Meloxicam; D016595:Misoprostol / Q000627:therapeutic use; D000077430:Nabumetone; D000078183:Oxindoles; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D016861:Cyclooxygenase Inhibitors; D016207:Cytokines; D007211:Indoles; D007527:Isoenzymes; D000078183:Oxindoles; D013843:Thiazines; D013844:Thiazoles; D016595:Misoprostol; C062866:tenidap; D000077430:Nabumetone; D000077239:Meloxicam